Viewing nowLyrica 25 mg (Pregabalin)
Pregabalin 25mg
Tablet · Prescription medication
Widers Pharmaceutical Co., Ltd.

MFDS item code 202108022 · Approved 2021.12.20 · Insurance code 660703730
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medication is used to treat peripheral and central neuropathic pain in adults. It is also used as an adjunctive treatment for partial seizures, with or without secondary generalized symptoms, in patients with epilepsy. Additionally, it is applied to alleviate the symptoms of fibromyalgia. In summary, this medication controls various nerve-related pain and epilepsy seizures and is effectively used in the treatment of fibromyalgia.
This medicine, as pregabalin, is administered orally twice daily in divided doses, regardless of food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and, based on efficacy and tolerability, may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined by the following formula. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplementary dose should be administered immediately after each 4-hour hemodialysis session. [Table 1] Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplementary dose after hemodialysis: 25, 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the method of administration. b: The supplementary dose refers to a dose administered as a single additional dose. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
7. Pediatric and adolescent patients Administration is not recommended for children under 12 years of age or adolescent patients aged 12-17 years because sufficient safety and efficacy data are not available.
This medication may increase the risk of suicidal thoughts or behavior, so careful monitoring for symptoms such as depression, mood changes, or unusual behavior is necessary while taking it. Patients with an allergy to pregabalin or any components of this medication should not take it. Diabetic patients should be cautious, as dosage adjustments of blood glucose control medications may be necessary due to weight gain. If serious allergic reactions such as angioedema occur, the medication should be discontinued immediately. Elderly patients should be especially careful during the initial dosing due to risks of falls or injuries from dizziness or drowsiness. Blurred vision or changes in eyesight may occur, and if such symptoms arise, discontinuation of the medication may be considered. When discontinuing pregabalin, withdrawal symptoms such as insomnia, headaches, and anxiety may occur, so consultation with healthcare professionals is recommended. Patients with a history of drug abuse are at a high risk for abuse with this medication and should take special precautions. Patients with impaired kidney function may require dosage adjustments. Patients with heart conditions should also take this medication with caution and consult a healthcare professional if symptoms of heart failure appear. When used in combination with other central nervous system depressants or opioid analgesics, the risk of respiratory suppression may increase, so caution is needed. During early pregnancy, there may be a risk of fetal malformations, so it is advisable for pregnant women to avoid taking it, and women of childbearing age should use effective contraception. Women who are breastfeeding should consider stopping breastfeeding or discontinuing the medication, as the drug may be transferred into breast milk. Hazardous activities such as driving or operating machinery should be avoided until dizziness or drowsiness has fully resolved. If severe skin reactions occur, the medication should be stopped immediately and a healthcare professional should be notified. In case of overdose, symptoms such as confusion, drowsiness, and depression may occur, and immediate treatment at a hospital should be sought. Keep out of reach of children and do not transfer to a different container for safety.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly closed container to protect it from air and moisture, and keep it at room temperature between 1 to 30 degrees Celsius.
Light pink oval tablets
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 25mg
Tablet · Prescription medication
Widers Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.